Bristol-Myers Squibb ( NYSE:BMY ) First Quarter 2024 Results Key Financial Results Revenue: US$11.9b (up 4.7% from 1Q...
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....